Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA profile of high-grade B-cell lymphoma with 11q aberration

ABSTRACT: microRNA profile of high-grade B-cell lymphoma with 11q aberration

PROVIDER: PRJNA1186589 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

microRNA profile of high-grade B-cell lymphoma with 11q aberration

Project description:Background: High-grade B-cell lymphoma with 11q aberration (HGBCL-11q) is a rare germinal centre lymphoma with a typical gain/loss pattern on chromosome 11q, but without MYC translocation and with some features resembling Burkitt lymphoma (BL) and HGBCLs or germinal centre derived diffuse large B-cell lymphoma, not otherwise specified (GCB-DLBCL-NOS). The microRNA expression profile of HGBCL-11q is not characterised. We aim to analyse miRNA expression profile in HGBCL-11q, BL and in GCB-DLBCL-NOS. Methods: Next generation sequencing (NGS)-based microRNA profiling was performed for HGBCL-11q (n=6), BL (n=8), and also GCB-DLBCL-NOS without (n=3) and with MYC rearrangement (MYC-R) (n=7). Results: We identified 39 and 64 miRNAs differentiating HGBCL-11q from BL, and from GCB-DLBCL-NOS without MYC-R, respectively. We found that the expression level of miR-223-3p, miR-193b-3p, miR-29b-3p and miR-146a-5p simultaneously differentiated HGBCL-11q from BL, as well as from GCB-DLBCL-NOS without MYC-R. We found higher miRNA profile heterogeneity in HGBCL-11q than in BL. The analysis of MYC-regulated miRNA showed different profile in HGBCL-11q and in BL but demonstrated separation of HGBCL-11q and BL from GCB-DLBCL-NOS cases. Conclusion: microRNA profile of HGBCL-11q is different than that of BL and of GCB-DLBCL-NOS but more heterogeneous compared to BL.

2025-01-15 | GSE281999 | GEO

Burkitt-like lymphoma with 11q aberration

Project description:Morphological and genetic study of Burkitt-like lymphoma with 11q aberration

| PRJEB27947 | ENA

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [CYTOSCAN]

Project description:Burkitt-like lymphoma with 11q aberration (BLL-11q) is a new provisional category in the 2016 WHO classification. The limited number of reported cases does not allow to define whether this is a specific entity or it is a particular variant of other recognized categories such as Burkitt or diffuse large B-cell lymphoma. The genetic alterations involved in the pathogenesis of BLL-11Q are not known.

2019-02-19 | GSE116522 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [SNP6]

2019-02-19 | GSE116518 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [ONCOSCAN]

2019-02-19 | GSE116526 | GEO

Comprehensive immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration by flow-cytometry

Project description:Recently, a subset of MYC-translocation negative aggressive B-cell lymphomas resembling Burkitt lymphoma (BL) characterized by proximal gains and distal losses in the long arm of chromosome 11 has been described. In the 2016 revision of the WHO classification these MYC-translocation negative lymphomas have been introduced as new provisional entity designated “Burkitt-like lymphoma with 11q aberration” (MNBLL 11q). Here, we show a comprehensive flow-cytometry analysis of 10 MNBLL 11q cases, well characterized genetically and pathologically. Twenty-three cases of MYC-positive BL, including three cases carrying both MYC rearrangements and 11q aberration, served as controls. All MNBLL 11q were CD20+/CD10+/BCL6+/BCL2- /MUM1- /MYC+/EBV negative , presented a high proliferation rate and showed a three-year overall survival (80%) similar to BL patients, with no recurrence after the end of treatment. MNBLL 11q immunophenotype was similar to that of MYC-positive BL without and with 11q, except for less frequent CD38higher expression (10% MNBLL 11q vs 91% MYC-positive BL, p<0.001), less frequent diminished CD45 expression (90% vs 23%, p=0.001), and CD16/CD56 co-expression (60% vs 0%, p<0.001). Our findings suggest subtle but important differences in MNBLL 11q immunophenotypes and MYC-positive BLs, which could not only aid in the differential diagnosis but also in the understanding of the pathogenesis of MNBLL 11q.

2019-07-30 | GSE93002 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation

Project description:Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation

| PRJNA478946 | ENA

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [SNP6]

Project description:Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [SNP6]

| PRJNA478920 | ENA

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [CYTOSCAN]

Project description:Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [CYTOSCAN]

| PRJNA478928 | ENA

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [ONCOSCAN]

Project description:Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [ONCOSCAN]

| PRJNA478933 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data